Intervention

L-NMMA

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting1

Common conditions17

Lead sponsors shown6

Clinical trials

9 shown

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)NCT05660083 · 2023-01-12

Phase Ib of L-NMMA and PembrolizumabNCT03236935 · 2018-08-27

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsNCT02834403 · 2016-11-01

SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesNCT01744236 · 2013-04-01

Effect of DPP4 Inhibition on Growth Hormone SecretionNCT01701973 · 2013-01-01

Pathophysiology of Cardiometabolic Risk Factors in African AmericansNCT01122407 · 2010-01-01

Sildenafil to Treat HIV-Associated Pulmonary HypertensionNCT00327080 · 2006-05-12

The Effect of Lopinavir/Ritonavir on Endothelial FunctionNCT00076414 · 2004-01-01

Nitric Oxide and the Autonomic Nervous SystemNCT00178919 · 2002-08-01

Common conditions

Hypertension2 Obesity2 Classical Hodgkin Lymphoma1 DNA Repair-Deficiency Disorders1 Head and Neck Squamous Cell Carcinoma1 Healthy1 HER2-negative Breast Cancer1 HIV1 Malignant Melanoma1 Metaplastic Breast Carcinoma1 Metastatic Breast Cancer1 Metastatic Triple Negative Breast Cancer1 Non-Small Cell Lung Cancer1 Pure Autonomic Failure1 TNBC - Triple-Negative Breast Cancer1 Type 2 Diabetes1 Urothelial Carcinoma Bladder1

Leading sponsors

The Methodist Hospital Research Institute3 Vanderbilt University2 Amsterdam UMC, location VUmc1 National Heart, Lung, and Blood Institute (NHLBI)1 National Institutes of Health Clinical Center (CC)1 Vanderbilt University Medical Center1

Trial status mix

COMPLETED7

RECRUITING1

TERMINATED1

Phase mix

PHASE15

PHASE22

PHASE42

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.